- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Interventions
- NUV-1511
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 565
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bone Metastases, Castration-Resistant Prostate Cancer
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
- Conditions
- Prostate Carcinoma Metastatic to the Bone
- Interventions
- Enzalutamide, Radium ra 223 dichloride
- Drug · Radiation
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD0516, AZD9574
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- carbon-11 acetate, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
- Radiation · Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Enzalutamide, Venetoclax
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Interventions
- REGN5678, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
- Interventions
- ²¹²Pb-DOTAM-GRPR1
- Drug
- Lead sponsor
- Orano Med Theranostics, SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- enzalutamide, abiraterone, prednisone
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 527
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 382 more
- Conditions
- Prostate Cancer
- Interventions
- Bone marrow transplantation, Cytoxan, testosterone cypionate
- Procedure · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 3
- States / cities
- Evanston, Illinois • New York, New York • Portland, Oregon
- Conditions
- Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Talazoparib, Tazemetostat
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Placebo, Abiraterone acetate, Prednisone/prednisolone
- Drug
- Lead sponsor
- Cougar Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 51 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- MEDI3726 Post-Chemo, MEDI3726 Pre-Chemo, MEDI3726 & Enzalutamide Combo
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Norfolk, Virginia
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
- Conditions
- Prostatic Cancer, Castration-Resistant
- Interventions
- JSB462, AAA617
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 7 more
- Conditions
- Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Interventions
- Abiraterone Acetate, Prednisone\Prednisolone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 154 more
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- Testosterone cypionate, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
- Interventions
- LFA102
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 2 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Procedure · Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Abiraterone acetate, Prednisone, Placebo
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 982 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more